NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that it has received notice from the European Patent Office that it intends to grant a patent with claims covering certain pharmaceutical formulations of indibulin (ZIO-301) for oral administration and processes for manufacturing such formulations. The Company also announced that it has received a notice from the United States Patent and Trademark Office that it intends to grant a patent with claims covering certain methods for treating multidrug-resistant tumors or inhibiting metastasis with various pharmaceutical compounds, including indibulin.
